About
Michael D. Jenkinson qualified from the University of Liverpool in 1998. He undertook neurosurgical training at The Walton Centre, Liverpool between 2001 and 2010, which included three years as a clinical research fellow culminating in a PhD in Neuroscience (Imaging and Biology of Oligodendroglial Tumours). He was appointed as a Consultant Neurosurgeon and at The Walton Centre in March 2010. He was appointed Professor of Neurosurgery at The University of Liverpool in 2019.
In his current role as Sir John Fisher / RCS England Chair of Surgical Trials he has a remit to expand the surgical trials research portfolio across all surgical discipline and to develop the next generation of surgical clinical trialists.
His research interests include meningioma management (incidental tumours, seizures and quality of life), imaging and biology of brain metastases and interventional clinical trials in neurosurgery and neuro-oncology. He is the recipient of grants for basic science and clinical research from the MRC, Brain Tumour Charity and NIHR. He is the chief investigator on several NIHR-funded trials, including the multi-centre ROAM trial (Radiation versus Observation following surgical resection of Atypical Meningioma)[https://roam-trial.org.uk], STOP 'EM (Surgeons Trial Of Prophylaxis for Epilepsy in Meningioma)[https://www.stopem-trial.org.uk], SPRING (Seizure Prophylaxis in Glioma) and ReStart (Restarting DOAC after TBI) [https://restart-trial.org.uk]. He is a co-investigator on the NIHR funded FUTURE GB and PROSSPER trials. He led a pilot study to investigate the use of Ketogenic diet for patients with glioblastoma (KEATING).
He was the co-chief investigator on the NIHR funded BASICS trial (The British Antibiotic and Silver Impregnated Catheters for ventriculoperitoneal Shunts randomized controlled trial) that showed that antibiotic catheters reduced the infection rate from 6% to 2% and save £135,000 per infection averted - antibiotic shunts are now standard of care in UK neurosurgery.
He sub-specialises in neurosurgical oncology for meningioma, intrinsic brain tumours including awake craniotomy and intra-operative brain mapping for low grade glioma, midlineapproaches to intraventricular and deep intrinsic tumours.
He chairs the Academic Committee of the Society of British Neurological Surgeons. He is the National Neurosurgery Subspecialty Lead for RCSEng.